Latest News for: galectin-8

Edit

Corporate Presentation, August 2025 (Galectin Therapeutics Inc)

Public Technologies 19 Aug 2025
) Galectin Therapeutics Corporate Overview ... Developing galectin-based therapeutics to improve the lives of patients with chronic liver diseases and cancer ... Belapectin is a novel, potent, galectin-3 inhibitor with Fast Track Designation.
Edit

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update

Nasdaq Globe Newswire 14 Aug 2025
14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc.
Edit

Galectin Therapeutics Reports Financial Results for the quarter ended June 30, 2025 and Provides Business Update (Form 8-K) (Galectin Therapeutics Inc)

Public Technologies 14 Aug 2025
) Galectin Therapeutics Reports Financial Results for the quarter ended June 30, 2025 and Provides Business Update. NORCROSS, Ga., August 14, 2025 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc ... About Galectin Therapeutics ... Galectin Therapeutics Inc.
Edit

Quarterly Report for Quarter Ending June 30, 2025 (Form 10-Q) (Galectin Therapeutics Inc)

Public Technologies 14 Aug 2025
... galectin proteins have a demonstrated role in the pathogenesis of a given disease ... Galectins, in particular galectin-3, act as a molecular glue, bringing together molecules that have sugars on them.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Galectin Therapeutics Inc)

Public Technologies 22 Jul 2025
) FORM 4. Check this box if no longer subject to Section 16 ... See Instruction 1(b) ... 0.5 ... GALECTIN THERAPEUTICS INC [GALT] 5 ... C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240 3 ... C/O GALECTIN THERAPEUTICS INC ... Galectin Therapeutics Inc.
Edit

Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through June 2026 (Form 8-K) (Galectin Therapeutics Inc)

Public Technologies 09 Jul 2025
) Galectin Therapeutics Announces New $10 Million Credit Line from Richard E ... NORCROSS, Ga., July 9, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc ... Uihlein, Chairman of Galectin Board of Directors, and its largest individual stockholder.
Edit

Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover ...

Nasdaq Globe Newswire 09 Jul 2025
Uihlein, Chairman of Galectin Board of Directors, and its largest individual stockholder.
Edit

KOL Event Presentation, June 2025 (Galectin Therapeutics Inc)

Public Technologies 16 Jun 2025
Galectin Company Introduction Joel Lewis (CEO C President) ... Belapectin a galectin-3 inhibitor reduced galectin-3 expression and fibrogenic activity in pre-clinical studies2,3,4 ... Galectin Therapeutics Inc.
Edit

Regulation FD Presentation (Form 8-K) (Galectin Therapeutics Inc)

Public Technologies 16 Jun 2025
). The text version of this document is not available ... Galectin Therapeutics Inc.
Edit

Annual Statement of Changes in Beneficial Ownership (Form 5) (Galectin Therapeutics Inc)

Public Technologies 11 Jun 2025
) FORM 5. Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 3 Holdings Reported. Form 4 Transactions Reported ... OMB Number ... GALECTIN THERAPEUTICS INC [GALT] 5 ... Galectin Therapeutics Inc.
Edit

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis ...

Nasdaq Globe Newswire 10 Jun 2025
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
Edit

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update

Nasdaq Globe Newswire 15 May 2025
... 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc.
Edit

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update (Form 8-K) (Galectin Therapeutics Inc)

Public Technologies 15 May 2025
) Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update. NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc ... About Galectin Therapeutics ... Galectin Therapeutics Inc.
Edit

Quarterly Report for Quarter Ending March 31, 2025 (Form 10-Q) (Galectin Therapeutics Inc)

Public Technologies 15 May 2025
... galectin proteins have a demonstrated role in the pathogenesis of a given disease ... Galectins, in particular galectin-3, act as a molecular glue, bringing together molecules that have sugars on them.
Edit

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the ...

Nasdaq Globe Newswire 12 May 2025
NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.�(NASDAQ.GALT), the ...

Article Search

tools
×
×
×
×